237 related articles for article (PubMed ID: 32552012)
1. Development of evocalcet for unmet needs among calcimimetic agents.
Hamano N; Endo Y; Kawata T; Fukagawa M
Expert Rev Endocrinol Metab; 2020 Sep; 15(5):299-310. PubMed ID: 32552012
[TBL] [Abstract][Full Text] [Related]
2. Head-to-head comparison of the new calcimimetic agent evocalcet with cinacalcet in Japanese hemodialysis patients with secondary hyperparathyroidism.
Fukagawa M; Shimazaki R; Akizawa T;
Kidney Int; 2018 Oct; 94(4):818-825. PubMed ID: 30049473
[TBL] [Abstract][Full Text] [Related]
3. Comparative Effectiveness of Calcimimetic Agents for Secondary Hyperparathyroidism in Adults: A Systematic Review and Network Meta-analysis.
Palmer SC; Mavridis D; Johnson DW; Tonelli M; Ruospo M; Strippoli GFM
Am J Kidney Dis; 2020 Sep; 76(3):321-330. PubMed ID: 32475604
[TBL] [Abstract][Full Text] [Related]
4. Evocalcet: A New Oral Calcimimetic for Dialysis Patients With Secondary Hyperparathyroidism.
Akizawa T; Ikejiri K; Kondo Y; Endo Y; Fukagawa M
Ther Apher Dial; 2020 Jun; 24(3):248-257. PubMed ID: 31486206
[TBL] [Abstract][Full Text] [Related]
5. Pharmacodynamics of evocalcet for secondary hyperparathyroidism in Japanese hemodialysis patients.
Shigematsu T; Shimazaki R; Fukagawa M; Akizawa T;
Clin Exp Nephrol; 2019 Feb; 23(2):258-267. PubMed ID: 30159688
[TBL] [Abstract][Full Text] [Related]
6. [Pharmacological and clinical profiles of a novel calcimimetic, evocalcet (ORKEDIA
Tokunaga S; Endo Y; Kawata T
Nihon Yakurigaku Zasshi; 2019; 154(1):35-43. PubMed ID: 31308348
[TBL] [Abstract][Full Text] [Related]
7. A novel calcimimetic agent, evocalcet (MT-4580/KHK7580), suppresses the parathyroid cell function with little effect on the gastrointestinal tract or CYP isozymes in vivo and in vitro.
Kawata T; Tokunaga S; Murai M; Masuda N; Haruyama W; Shoukei Y; Hisada Y; Yanagida T; Miyazaki H; Wada M; Akizawa T; Fukagawa M
PLoS One; 2018; 13(4):e0195316. PubMed ID: 29614098
[TBL] [Abstract][Full Text] [Related]
8. Long-Term Efficacy and Safety of Evocalcet in Japanese Patients with Secondary Hyperparathyroidism Receiving Hemodialysis.
Yokoyama K; Shimazaki R; Fukagawa M; Akizawa T;
Sci Rep; 2019 Apr; 9(1):6410. PubMed ID: 31015494
[TBL] [Abstract][Full Text] [Related]
9. A Systematic Review and Meta-analysis of Efficacy and Safety of Calcimimetic Agents in the Treatment of Secondary Hyperparathyroidism in Patients with Chronic Kidney Disease.
Liu Y; Yang Q; Chen G; Zhou T
Curr Pharm Des; 2022; 28(40):3289-3304. PubMed ID: 36305135
[TBL] [Abstract][Full Text] [Related]
10. Cinacalcet HCl: a novel treatment for secondary hyperparathyroidism caused by chronic kidney disease.
Torres PU
J Ren Nutr; 2006 Jul; 16(3):253-8. PubMed ID: 16825031
[TBL] [Abstract][Full Text] [Related]
11. Evocalcet prevents ectopic calcification and parathyroid hyperplasia in rats with secondary hyperparathyroidism.
Sakai M; Tokunaga S; Kawai M; Murai M; Kobayashi M; Kitayama T; Saeki S; Kawata T
PLoS One; 2020; 15(4):e0232428. PubMed ID: 32343734
[TBL] [Abstract][Full Text] [Related]
12. Calcimimetics for secondary hyperparathyroidism in chronic kidney disease patients.
Ballinger AE; Palmer SC; Nistor I; Craig JC; Strippoli GF
Cochrane Database Syst Rev; 2014; 2014(12):CD006254. PubMed ID: 25490118
[TBL] [Abstract][Full Text] [Related]
13. The impact of cinacalcet in the mineral metabolism markers of patients on dialysis with severe secondary hyperparathyroidism.
Bucharles SGE; Barreto FC; Riella MC
J Bras Nefrol; 2019 Jul; 41(3):336-344. PubMed ID: 31419274
[TBL] [Abstract][Full Text] [Related]
14. Activation of the Calcium Receptor by Calcimimetic Agents Is Preserved Despite Modest Attenuating Effects of Hyperphosphatemia.
Goodman WG; Ward DT; Martin KJ; Drayer D; Moore C; Xu J; Lai J; Chon Y; Nemeth EF
J Am Soc Nephrol; 2022 Jan; 33(1):201-212. PubMed ID: 34732508
[TBL] [Abstract][Full Text] [Related]
15. Phase 2b study of evocalcet (KHK7580), a novel calcimimetic, in Japanese patients with secondary hyperparathyroidism undergoing hemodialysis: A randomized, double-blind, placebo-controlled, dose-finding study.
Akizawa T; Shimazaki R; Fukagawa M;
PLoS One; 2018; 13(10):e0204896. PubMed ID: 30379826
[TBL] [Abstract][Full Text] [Related]
16. Treatment of secondary hyperparathyroidism: How do cinacalcet and etelcalcetide differ?
Eidman KE; Wetmore JB
Semin Dial; 2018 Sep; 31(5):440-444. PubMed ID: 30009474
[TBL] [Abstract][Full Text] [Related]
17. Etelcalcetide for the treatment of secondary hyperparathyroidism.
Hamano N; Komaba H; Fukagawa M
Expert Opin Pharmacother; 2017 Apr; 18(5):529-534. PubMed ID: 28277829
[TBL] [Abstract][Full Text] [Related]
18. Evocalcet with vitamin D receptor activator treatment for secondary hyperparathyroidism.
Shigematsu T; Asada S; Endo Y; Kawata T; Fukagawa M; Akizawa T
PLoS One; 2022; 17(2):e0262829. PubMed ID: 35176038
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics, Pharmacodynamics, and Safety of the Novel Calcimimetic Agent Evocalcet in Healthy Japanese Subjects: First-in-Human Phase I Study.
Akizawa T; Shimazaki R; Shiramoto M; Fukagawa M;
Clin Drug Investig; 2018 Oct; 38(10):945-954. PubMed ID: 30168004
[TBL] [Abstract][Full Text] [Related]
20. Cinacalcet studies in pediatric subjects with secondary hyperparathyroidism receiving dialysis.
Warady BA; Ng E; Bloss L; Mo M; Schaefer F; Bacchetta J
Pediatr Nephrol; 2020 Sep; 35(9):1679-1697. PubMed ID: 32367309
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
